Ningning Zhang

Peking University — China

Medicine · Health Sciences

6h-index201citations28works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(12), Ferroptosis and cancer prognosis(9), RNA modifications and cancer(8), Liver Disease Diagnosis and Treatment(7), Epigenetics and DNA Methylation(6)

Publications28 total

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression
2025Open Access
Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Data from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Table S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Abstract P3-02-29: The mechanism of acidic microenvironment promotes tumor-associated macrophages secreting glutamine to activate dual signaling pathways of mTORC1 and c-MYC in CDK4/6 inhibitor resistance of ER-positive breast cancer
Clinical Cancer Research·2025
Liver protection of CACA technical guidelines for holistic integrative management of cancer
Holistic Integrative Oncology·2025· 1 citedOpen Access
Fecal microbiota transplantation alleviates cirrhotic portal hypertension in rats via butyrate-mediated HDAC3 inhibition and PI3K/Akt/eNOS signaling regulation
European Journal of Pharmacology·2025· 6 cited
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Clinical Cancer Research·2025· 2 cited
Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8+ T-cell-mediated antitumor immunity in liver cancer
Acta Pharmaceutica Sinica B·2024· 6 citedOpen Access
SAT-491 Assessing the relationship between human plasma metabolites and hepatocellular carcinoma: a two-sample Mendelian randomization analysis
Journal of Hepatology·2024
Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma
Cancer Biology and Medicine·2024· 10 citedOpen Access
Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer
JHEP Reports·2024· 16 citedOpen Access
Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression
2023Open Access
Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Hongfeng Yuan(11), Huihui Zhang(11), Chunyu Hou(11), Xiaodong Zhang(11), Ming Luo(11), Yufei Wang(10), Haolin Yun(10), Jinyan Feng(10), Liang Xu(10), Guang Yang(10), Wei Lü(10), Tian Liu(10), Jihui Hao(10), Shukui Qin(10), Yanqiao Zhang(10), Gang Wang(10), Yajin Chen(10), Jingdong Zhang(10), Shanzhi Gu(10), Junqi Niu(10)